Oxaliplatin(Aiheng)

DRUG2 trials

Sponsors

The First Affiliated Hospital of Henan University of Science and Technology

Conditions

Esophageal NeoplasmsStage II Esophageal Squamous Cell CarcinomaStage III Esophageal Squamous Cell Carcinoma

Phase 3

Chemoradiotherapy of Capecitabine With or Without Oxaliplatin Versus Cisplatin-5-FU for Esophageal Squamous Cancer

The First Affiliated Hospital of Henan University of Science and TechnologyStage II Esophageal Squamous Cell Carcinoma, Stage III Esophageal Squamous Cell Carcinoma

Start: 2014-10-31End: 2025-04-01Updated: 2023-02-08

The Role of Different Cycles of Chemotherapy（Capecitabine-oxaliplatin） in Esophageal Chemoradiotherapy

The First Affiliated Hospital of Henan University of Science and TechnologyEsophageal Neoplasms, Stage III Esophageal Squamous Cell Carcinoma

Start: 2014-10-31End: 2020-12-31Target: 60Updated: 2016-07-06

Related Papers

X versus XELOX versus PF in definitive concurrent chemoradiotherapy (DCRT) for local-advanced squamous esophageal cancer (ESCC): 2021 update from a multicenter, open-label, randomized III trial, CRTCOESC trial.

Journal of Clinical Oncology2022-01-19

X versus XELOX versus PF in definitive concurrent chemoradiotherapy (DCRT) for local advanced squamous esophageal cancer (ESCC): Update from a multicenter, open-label, randomized III trial, CRTCOESC trial.

Journal of Clinical Oncology2020-05-20

A randomized, open-label, multicenter trial of the concurrent chemoradiotherapy of capecitabine with or without oxaliplatin versus cisplatin with 5-FU for Chinese squamous esophageal cancer: An interim report from CRTCOESC.

Journal of Clinical Oncology2017-05-203 citations